JENKINS DAVID A 4

4 · Ra Medical Systems, Inc. · Filed Mar 27, 2023

Form 4

Period: 2023-03-23

DirectorChairman of the Board and CEO

Transactions

Conversion
Series X Convertible Preferred Stock
2023-03-23−277.597→ 2,292.339 total
Exercise: $0.00→ Common Stock (2,292,339 underlying)
Conversion
Common Stock
2023-03-23+277,597→ 277,597 total
Conversion
Common Stock
2023-03-23+709,703→ 709,703 total(indirect: See footnote)
Conversion
Common Stock
2023-03-23+2,264→ 2,264 total(indirect: See footnote)
Conversion
Series X Convertible Preferred Stock
2023-03-23−709.703→ 5,860.54 total(indirect: See footnote)
Exercise: $0.00→ Common Stock (5,860,540 underlying)
Conversion
Series X Convertible Preferred Stock
2023-03-23−2.264→ 18.691 total(indirect: See footnote)
Exercise: $0.00→ Common Stock (18,691 underlying)

Footnotes (5)

[F1]This transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.
[F2]Shares held by a partnership of which the reporting person is the managing member of the managing partner.
[F3]Shares held by charitable remainder unitrust of which the reporting person's spouse is the trustee.
[F4]Each share of preferred stock will automatically convert into 1000 shares of common stock on or after July 9, 2024, if the Company satisfies the initial listing standards of a national securities exchange or has been delisted from the NYSE American.
[F5]Series X Convertible Preferred Stock has no expiration date.

Documents

1 file